BCL2 and diffuse large B-cell lymphoma: Our data from single and combinatorial drug screens show that inhibitors of Bcl-2 and BTK or PI3K act synergistically to kill DLBCL cells that exhibit high Bcl-2 expression due to either BCL2 translocations or amplifications.